ERASErasca, Inc.vs its industry peers
A metric-by-metric comparison of Erasca, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERASThis | $5.6B#6 | — | 14.3x#2 | — | — | 23.0%#2 | — | -31.6%#3 | — | — | 1186.5%#1 | — |
| INSM | $21.4B#2 | — | 30.3x#5 | 35.2x#4 | 66.7%#3 | -39.7%#4 | -205.6%#4 | -181.1%#5 | -185.1%#1 | 4#1 | -8.1%#2 | — |
| SMMT | $10.4B#5 | — | 16.5x#3 | — | — | -387.8%#5 | — | -171.4%#4 | — | — | — | — |
| UTHR | $22.0B#1 | 19.1x#1 | 3.7x#1 | 6.9x#1 | 10.6%#4 | 11.7%#3 | 46.9%#1 | 22.6%#1 | — | — | — | — |
| ARWR | $11.9B#4 | — | 19.4x#4 | 14.4x#2 | 23258.2%#1 | 99.7%#1 | 11.9%#2 | -0.3%#2 | — | — | — | — |
| BBIO | $15.7B#3 | — | — | 31.2x#3 | 126.3%#2 | — | -104.2%#3 | — | — | — | — | 0.0%#1 |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-08-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice